Anticancer research
-
Anticancer research · Feb 2012
Case ReportsMetastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Six targeted agents [sorafenib, sunitinib, temsirolimus, bevacizumab (plus interferon), everolimus and pazopanib] have been approved for the treatment of patients with metastatic renal cell carcinoma. As disease progression is inevitable, most patients will receive several lines of treatment. ⋯ We report the case of a 63-year-old woman who responded for 24 months to three successive lines of treatment with different TKIs (sunitinib, axitinib and sorafenib). This suggests that TKIs targeting VEGFR should be considered as individual drugs and not as a single class.
-
The goal was to analyze the link between blood levels of calcidiol and all-cause, cardiac and infectious diseases, and mortality due to cancer in hemodialysis patients. ⋯ These data highlight the need to ensure primarily adequate 25(OH)D levels in dialysis patients for an advantage of survival.
-
Anticancer research · Nov 2011
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres. The safety, feasibility and efficacy of prolonged temozolomide administration in patients with anaplastic gliomas was evaluated. ⋯ Prolonged administration of adjuvant temozolomide is safe and can be favorable for patients with anaplastic gliomas.
-
Anticancer research · Nov 2011
Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer.
To assess pelvic (P) and/or paraaortic (PA) lymph node (LN) involvement in patients with primary stage IA-IVA cervical cancer, (18)F-fluorodeoxyglucose (FDG)-PET, and MRI were compared with histological results. ⋯ FDG-PET is less accurate than MRI for PLN, but more accurate for PALN; FDG-PET cannot replace PA surgical procedures, but could guide them.
-
Anticancer research · Oct 2011
Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
The aim of the study was to compare two different neurotoxicity scales in grading chemotherapy-induced neurotoxicity. ⋯ The oxaliplatin and NCI-CTC sensory scales were comparable in identifying chemotherapy-induced neuropathy, but the oxaliplatin scale more often detected the progression of the symptoms.